Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brepocitinib dose-ranging study in active systemic lupus erythematosus
2018-004175-12Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Pfizer. Primary endpoint: SRI-4 response at Week 52. Started Jul 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-004175-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004175-12.